One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma

Allergology International

Volumn 59, Issue 2, 2010, Pages 167-174

  Ohta, Ken ^a   Yamamoto, Manabu ^b   Sato, Norio ^b   Ikeda, Kimitoshi ^b   Miyamoto, Terumasa ^c  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

^c Japan Clinical Allergy Research Institute   (Japan)

Author keywords

Asthma; Efficacy; Japanese; Omalizumab; Safety evaluation

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASTHMA; BACKACHE; BODY WEIGHT; CLINICAL TRIAL; DENTAL CARIES; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG MEGADOSE; ECZEMA; ENTEROCOLITIS; FEMALE; FORCED EXPIRATORY VOLUME; GASTRITIS; GASTROENTERITIS; GLUCOSURIA; HEADACHE; HIATUS HERNIA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; JAPAN; JAPANESE; LEUKOCYTE COUNT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SIDE EFFECT; SORE THROAT; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; BLOOD; DISEASE COURSE; DRUG RESISTANCE; DRUG SCREENING; FOLLOW UP; IMMUNOLOGY; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DISEASE PROGRESSION; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 77954561297     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.09-OA-0137     Document Type: Article

References (27)

1. Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005;83:548-54.
2. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-7.
3. Dolan CM, Fraher KE, Bleecker ER et al. Designand baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92: 32-9.
4. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35: 657-65.
5. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23: 287-91.
6. Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 2005;60(Suppl2):21.
7. Rabe KF, Adachi M, Lai CK et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7.
8. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
9. Peters SP, Jones CA, Haselkorn T et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119:1454-61.
10. [Annual population survey report from the Ministry of Health, Labour and Welfare of Japan 2007] (in Japanese). Available at: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai07/toukei6.html. Accessed May 15, 2009.
11. Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-32.
12. Shields RL, Whether WR, Zioncheck K et al. Inhibition of allergic reactions with antibody to IgE. Int Arch Allergy Immunol 1995;107:308-12.
13. Humbert M, Beasley R, Ayres J et al. Benefits of omalizu-mab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.
14. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701-8.
15. Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omali-zumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17.
16. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
17. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-9.
18. Solèr M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61. Erratum in: Eur Respir J 2001; 18: 739-40.
19. Buhl R, Solèr M, MatzJet al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-8.
20. Holgate ST, Chuchalin AG, Hébert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8.
21. Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, and 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate to severe persistent asthma. Respirology 2009;14:1156-65.
22. Ministry of Health and Welfare, Japan. Asthma Prevention and Management Guidelines. Int Arch Allergy Immunol 2000; 121 (Suppl 1):1-77.
23. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication No 023659. Revised 2007. Available at: http://www.ginasthma.org. Accessed May 15, 2009.
24. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.
25. Ädelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253-9.
26. Casale TB, Bernstein IL, Busse WW et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21.
27. National Asthma Education and Prevention Program. Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma. Accessed May 15, 2009.